Author Archives: Dan Stanton

PerkinElmer continues M&A path with $5.25bn BioLegend deal

PerkinElmer is set to add antibody and reagent supplier BioLegend in a deal that analysts say could transform its Discovery and Analytical Solutions (DAS) business into a high growth segment. The acquisition announced yesterday and expected to close by the end of the year will see life sciences giant PerkinElmer pay $5.25 billion – including $2.2 billion in stock consideration – for private antibody and reagent developer BioLegend. The proposed deal xpands PerkinElmer into the “fast growing, high margin, antibody…

With $100m in hand, Kriya set to bring GMP gene therapy plant online

Kriya Therapeutics will use $100 million from a Series B funding to develop its gene therapy manufacturing platforms and says its GMP plant in North Carolina will come online this year. The Series B financing – led by Patient Square Capital, with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others – closed earlier this month. The funding will help support Kriya’s gene therapy platforms and manufacturing infrastructure, which aim to reduce the cost of…

From baking to bioprocessing: Lumen leases Seattle plant to advance ‘edible’ antibodies

Spirulina-based antibody developer Lumen Biosciences will convert a bakehouse into a biologics plant capable of producing 15 kg per week of cGMP-grade drug substance. Seattle, Washington-based Lumen turns spirulina – protein-rich cyanobacteria touted by many health enthusiasts as a ‘superfood’ – into tiny factories that churn out therapeutic antibodies. To support the development of its candidates, the firm has expanded its manufacturing footprint by leasing a former bakery in the Fremont-Wallingford neighborhood of Seattle. “All of our current products are…

Second Bluebird gene therapy approval a boon for Minaris

CDMO Minaris says it will be the commercial manufacturer for Skysona (elivaldogene autotemcel, Lenti-D), a second Bluebird Bio gene therapy approved by the European Commission. The European Commission (EC) granted marketing authorization of Skysona for the treatment of early cerebral adrenoleukodystrophy (CALD) yesterday. The one-time gene therapy uses a patient’s own hematopoietic stem cells (HSC) to treat the underlying cause of the neurologic condition CALD. SKYSONA uses ex vivo transduction with the Lenti-D lentiviral vector (LVV) to add functional copies…

Humira: AbbVie’s biosimilar erosion woes may be overstated

An analyst says general forecasts of biosimilar erosion for Humira (adalimumab) are too pessimistic as the size of the brand could still present upsides for AbbVie. AbbVie’s monoclonal antibody Humira continues to be the world’s top selling drug, despite biosimilar competition hitting sales outside of the US over the past few years. In 2020, global sales stood at $19.8 billion, $16.1 billion of which came from the US. As it stands, legal agreements between AbbVie and a host of biosimilar…

Forge Bio wins GentiBio AAV vector contract

Forge Bio will develop and manufacture adeno-associated viral (AAV) vectors for GentiBio’s engineered Tregs candidates from its site in Columbus, Ohio. The deal will see contract development and manufacturing organization (CDMO) Forge Bio use its Blaze Vector production platform and HEK 293 Suspension Ignition Cells to support GentiBio’s preclinical and clinical programs. The work will be undertaken at Forge Bio’s facilities at The Hearth, Columbus, which has grown through heavy investment over the past year. “Forge has rapidly expanded our…

Rebranded AMRI on spending spree with LakePharma and Integrity buys

A new name, the purchase of biomanufacturer LakePharma, and the addition of fill-finish firm Integrity Bio. All in a week’s work for Curia, the CDMO previously known as AMRI. Contract development and manufacturing organization (CDMO) AMRI rebranded itself this week as Curia before announcing a double acquisition expected to boost its capacity and capabilities in the manufacturing services space. The first deal sees the CDMO acquire Integrity Bio, a privately held formulation and fill-finish organization headquartered in Camarillo, California. Financials…

Poseida joins Cellares’ early-access cell therapy tech program

Cellares Corporation has added a third firm to its early-stage partnership program, giving Poseida Therapeutics access to its closed and automated cell therapy manufacturing platform. Californian firm Cellares is looking to overcome limitations in current advanced therapy manufacturing through the development of its manufacturing platform, the Cell Shuttle. The Cell Shuttle is a modular and automated solution comprising hardware, software, robotics and consumables and according to the firm is capable of producing 10 patient doses simultaneously. Since 2020, the firm…

Chinese CDMOs eye advanced therapies and global markets

Univercells Technologies says traditional small molecule Chinese CDMOs are rapidly expanding into the cell and gene therapy space as it partners with viral vector producer VectorBuilder. The partnership will see Univercells Technologies – a bioprocess technology firm under KKR’s Gamma Biosciences umbrella – work with VectorBuilder’s manufacturing center in Guangzhou, China to develop and optimize platform processes for the production of custom viral vectors for both cell and gene therapies and vaccine applications. “Through this partnership, both parties will leverage…

Thermo Fisher opens Korean bioprocess center

The Bioprocess Design Center (BDC) in Incheon, Korea will offer support to the region’s continually growing biomanufacturing industry, says Thermo Fisher. The Songdo, Incheon BDC opened its doors earlier this month with the aim “to help enhance the competitiveness of the Korean bio industry,” Scott Song, director of BioProduction and Laboratory Chemical at Thermo Fisher Scientific, said during a promotional video announcing the opening of the site. “The BDC will play a pivotal role in realizing Thermo Fisher Scientific’s vision…